[go: up one dir, main page]

AR099328A1 - Conjugados de factor vii - Google Patents

Conjugados de factor vii

Info

Publication number
AR099328A1
AR099328A1 ARP150100377A ARP150100377A AR099328A1 AR 099328 A1 AR099328 A1 AR 099328A1 AR P150100377 A ARP150100377 A AR P150100377A AR P150100377 A ARP150100377 A AR P150100377A AR 099328 A1 AR099328 A1 AR 099328A1
Authority
AR
Argentina
Prior art keywords
factor vii
heparosan
vii polypeptide
heparosan polymer
vii conjugates
Prior art date
Application number
ARP150100377A
Other languages
English (en)
Inventor
Behrens Carsten
Dr Deangelis Paul
Michael Haller Friedrich
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR099328A1 publication Critical patent/AR099328A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se refiere a la conjugación de polipéptidos del Factor VII con polímeros de heparosano. Los conjugados resultantes se pueden utilizar para suministrar el Factor VII, por ejemplo, en el tratamiento o la prevención de un trastorno hemorrágico. Reivindicación 1: Un conjugado que comprende un polipéptido del Factor VII, un resto conector y un polímero de heparosano, donde el resto conector entre el polipéptido del Factor VII y el polímero de heparosano comprende X tal como se indica a continuación: [polímero de heparosano] - [X] - [polipéptido del Factor VII] donde X comprende un derivado de ácido siálico que está conectado a un resto de acuerdo con la fórmula (1).
ARP150100377A 2014-02-12 2015-02-10 Conjugados de factor vii AR099328A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14154875 2014-02-12

Publications (1)

Publication Number Publication Date
AR099328A1 true AR099328A1 (es) 2016-07-13

Family

ID=50071543

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100377A AR099328A1 (es) 2014-02-12 2015-02-10 Conjugados de factor vii

Country Status (13)

Country Link
US (1) US20150225711A1 (es)
EP (1) EP3104894A1 (es)
JP (1) JP2017507133A (es)
KR (1) KR20160122158A (es)
CN (1) CN106358440A (es)
AR (1) AR099328A1 (es)
AU (1) AU2015216988A1 (es)
BR (1) BR112016017644A2 (es)
CA (1) CA2939577A1 (es)
IL (1) IL246349A0 (es)
MX (1) MX2016010229A (es)
RU (1) RU2016134328A (es)
WO (1) WO2015121385A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150259665A1 (en) * 2012-10-15 2015-09-17 Novo Nordisk Health Care Ag Factor vii conjugates
KR20160065925A (ko) 2013-10-15 2016-06-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 응고 인자 vii 폴리펩티드
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
CN107118277B (zh) * 2017-07-12 2020-12-04 苏州博赛生物医药有限公司 一种单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0614839A2 (pt) * 2005-08-19 2009-05-19 Neose Technologies Inc fator vii e fator viia glicopeguilados
US20090055942A1 (en) * 2005-09-14 2009-02-26 Novo Nordisk Healthcare A/G Human Coagulation Factor VII Polypeptides
US9687559B2 (en) * 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
WO2011101242A1 (en) * 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
US20150259665A1 (en) * 2012-10-15 2015-09-17 Novo Nordisk Health Care Ag Factor vii conjugates
CN105008530A (zh) * 2013-03-12 2015-10-28 诺和诺德股份有限公司 凝血酶敏感性凝固因子x分子

Also Published As

Publication number Publication date
CN106358440A (zh) 2017-01-25
EP3104894A1 (en) 2016-12-21
BR112016017644A2 (pt) 2017-10-17
JP2017507133A (ja) 2017-03-16
AU2015216988A1 (en) 2016-07-07
CA2939577A1 (en) 2015-08-20
IL246349A0 (en) 2016-08-31
KR20160122158A (ko) 2016-10-21
US20150225711A1 (en) 2015-08-13
MX2016010229A (es) 2016-11-15
WO2015121385A1 (en) 2015-08-20
RU2016134328A (ru) 2018-03-15

Similar Documents

Publication Publication Date Title
CO2020003478A2 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CO2020001498A2 (es) Derivados de 6-amino-7,9-dihidro-8h-purina-8-ona como agonistas inmunoestimulantes del receptor 7 tipo toll (tlr7)
CL2016001514A1 (es) Conjugado de anticuerpo-farmaco que posee un resto quimico no peptidico, que puede ser escindido por la catepsina b; uso para la fabricacion de un medicamento util y conjugacion farmaceutica.
MX2016010533A (es) Conjugado anticuerpo anti-factor de crecimiento epidermico humano 3 (anti-her3-farmaco).
CO2020001502A2 (es) Agonistas del receptor tipo toll 7 (tlr7) que tienen una porción heterobiarilo, conjugados de estos y métodos y usos de estos
BR112015027321A2 (pt) composições e métodos
BR112014019990A8 (pt) Compostos enediinos, seus conjugados e usos e métodos para esses compostos
UY36186A (es) Ácidos grasos novedosos y su uso en la conjugación con biomoléculas
BR112015019432A2 (pt) Compostos de tubulisina, métodos de produção e uso
UY36075A (es) Derivados de tubulisina
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PE20150288A1 (es) Dialisato a base de polimero
AR088694A1 (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
IN2014MN01819A (es)
CY1122899T1 (el) Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη
UY31785A1 (es) Sistema polimerico de lagrimas artificiales
AR095072A1 (es) Conjugados antibióticos
AR090307A1 (es) Polimeros cationicos a base de glucogeno
CR20150211A (es) Compuestos diméricos
MX2024000877A (es) Conjugados polimero-farmaco escindibles.
MX2023004647A (es) Copolimeros de dibloque auto-montados compuestos de pegmema y segmentos polimericos que tienen farmaco.

Legal Events

Date Code Title Description
FB Suspension of granting procedure